Anti-PD-L1 immunotherapy is used to treat second-line or later Non-Small Cell Lung Cancer (NSCLC). These monoclonal antibodies are the therapy of choice against NSCLC in routine clinical practice.

**AIM AND OBJECTIVES**

To evaluate the efficacy of anti-PD-L1 immunotherapy in clinical practice in NSCLC.

**MATERIAL AND METHODS**

Retrospective observational study (July 2017-July 2020)

Efficacy of atezolizumab, nivolumab and pembrolizumab

Study variables

Patient data were obtained through the digital medical record and the oncology pharmacy computer program.

- In patients with NSCLC.
- After failing a first-line chemotherapy.
- Progression Free Survival (PFS)
- Overall Survival (OS)

Mean age: 66 years

Male sex predominated (89.4%)

Follow-up of 72 months

85 patients

- 23 received atezolizumab
- 47 received nivolumab
- 15 received pembrolizumab

**RESULTS**

<table>
<thead>
<tr>
<th></th>
<th>Median OS (months)</th>
<th>95%CI</th>
<th>Median PFS (months)</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATEZOLIZUMAB</td>
<td>15.75</td>
<td>0.00 - 33.08</td>
<td>6.83</td>
<td>4.89 - 8.77</td>
</tr>
<tr>
<td>NIVOLUMAB</td>
<td>4.7</td>
<td>2.87 - 6.58</td>
<td>3.12</td>
<td>2.14 - 4.10</td>
</tr>
<tr>
<td>PEMBROLIZUMAB</td>
<td>13.73</td>
<td>4.47 - 22.99</td>
<td>9.13</td>
<td>0.48 - 17.70</td>
</tr>
</tbody>
</table>

The results obtained were compared with the results of the pivotal clinical trials.

In atezolizumab, the median PFS of our study was much higher than that of the OAK1 Study. Median OS obtained is also higher than that of the OAK and the POPLAR2 Study.

The PFS results obtained from our study of nivolumab are similar to those obtained in the CheckMate-0573 and CheckMate-CA2090174 trials. For OS, we obtain a much smaller median than that of the pivotal trials. In pembrolizumab, the median PFS obtained is higher than obtained by Keynote 010 trial 5, although the OS values are the same.

**CONCLUSION AND RELEVANCE**

Our data indicate that the efficacy of anti-PDL1 immunotherapy in patients with second-line NSCLC in clinical practice varies respect to that obtained in pivotal clinical trials, obtaining a higher PFS and a similar OS, except with nivolumab, which was very lower. It would be interesting, in future studies, increase the number of patients to confirm these data on the efficacy of anti-PDL1 immunotherapy.